EU post-market surveillance - why it's not enough
This article was originally published in Clinica
Post-market surveillance is a misleading term. It apparently applies only to products after they have been put on the market. Yet manufacturers who ignore pre-clinical and design factors in the post-market assessment of product safety are at risk of product failures and liability problems in the current environment of regulatory change. Amanda Maxwell reports
You may also be interested in...
HAL Allergy Group, developer of products for allergy diagnostics and allergen immunotherapy, promoted its principal scientist to chief R&D officer; Starkey Hearing Technologies brought on new health and business development execs to expand its global footprint; and more.
As the coronavirus continues to spread, one of the big four global vaccines companies has committed itself to the fight.